Skip to main content
SpringerLink
Log in

Thrombolytic Therapy: Evidence-Based Results from Multicenter Control Trials

  • Chapter
Thrombolysis in Pulmonary Embolism

Abstract

The goal of this chapter is to offer a brief description of the main characteristics and lessons coming from the main randomized controlled trials, which were considered for inclusion in this chapter if thrombolysis by peripheral vein was evaluated as intervention and had a comparator group including low-molecular-weight heparin, fondaparinux, K-vitamin antagonists, or unfractionated heparin. In addition, mortality has to be considered (Chatterjee et al., JAMA 311:2414–2421, 2014). Full references are included if the reader wants to deepen the characteristics and results of the randomized control trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Konstantinides S, Torbicki A. Management of venous thromboembolism: an update. Eur Heart J. 2014;35:2855–63.

    Article  PubMed  Google Scholar 

  2. Tapson VF. Thrombolytic therapy for acute pulmonary embolism. Semin Thromb Hemost. 2013;39:452–8.

    Article  CAS  PubMed  Google Scholar 

  3. Konstantinides S, Goldhaber SZ. Pulmonary embolism: risk assessment and management. Eur Heart J. 2012;33:3014–22.

    Article  CAS  PubMed  Google Scholar 

  4. Chatterjee S, Chakraborty A, Weinberg I, Kadakia M, Wilensky RL, Sardar P, Kumbhani DJ, Mukherjee D, Jaff MR, Giri J. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014;311:2414–21.

    Article  PubMed  Google Scholar 

  5. The Urokinase Pulmonary Embolism Trial. Urokinase pulmonary embolism trial: phase 1 results: a cooperative study. JAMA. 1970;214:2163–72.

    Article  Google Scholar 

  6. Tibbutt DA, Davies JA, Anderson JA, Fletcher EWL, Hamill J, Holt JM, Thomas ML, Lee G, Miller GAH, Sharp AA, Sutton GC. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. Br Med J. 1974;1:343–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand. 1978;203:465–70.

    Article  CAS  PubMed  Google Scholar 

  8. Marini C, Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration. 1988;54:162–73.

    Article  CAS  PubMed  Google Scholar 

  9. Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest. 1990;98:1473–9.

    Article  CAS  PubMed  Google Scholar 

  10. PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism: a collaborative study by the PIOPED Investigators. Chest. 1990;97:528–33.

    Article  Google Scholar 

  11. Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, Zonzin P, Zanuttini D, Barbaresi F, Agnelli G, Morpurgo M, Marini MG, Visani L. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: Plasminogen Activator Italian Multicenter Study 2. J Am Coll Cardiol. 1992;20:520–6.

    Article  CAS  PubMed  Google Scholar 

  12. Goldhaber SZ, Come PC, Lee RT, Braunwald E, Parker JA, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, da Silva AM T, Mogtader A, McDonough TJ. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341:507–11.

    Article  CAS  PubMed  Google Scholar 

  13. Jerjes-Sanchez C, Ramirez-Rivera A, Garcia ML, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, Rosas E. Streptokinase and heparin vs heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2:227–9.

    Article  CAS  PubMed  Google Scholar 

  14. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Management strategies and prognosis of pulmonary embolism-3 trial investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347:1143–50.

    Article  CAS  PubMed  Google Scholar 

  15. Becattini C, Agnelli G, Salvi A, Grifoni S, Pancladi LG, Enea I, Blasemin F, Campanini M, Ghirarduzzi A, Casazza F, TIPES Study Group. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010;125:e82–6.

    Article  CAS  PubMed  Google Scholar 

  16. Lankeit M, Konstantinides S. Tenecteplase can be given to patients with intermediate-risk pulmonary embolism—but should it? Thromb Res. 2010;126:e407–8.

    Article  CAS  PubMed  Google Scholar 

  17. Fasullo S, Scalzo S, Maringhini G, Ganci F, Canizzaro S, Basile I, Cangemi D, Terrazzino G, Parrinello G, Sarullo FM, Baglini R, Paterna S, Di Pascuale P. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. Am J Med Sci. 2011;341:33–9.

    Article  PubMed  Google Scholar 

  18. Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M, for the “MOPETT” Investigators. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am J Cardiol. 2013;111:273–7.

    Article  PubMed  Google Scholar 

  19. Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Granca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV, PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370:1402–11.

    Article  CAS  PubMed  Google Scholar 

  20. Paul W, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F, for the STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2014;368:1379–87.

    Google Scholar 

  21. Elliot CG. Fibrinolysis of pulmonary emboli–steer closer to Scylla. N Engl J Med. 2014;370:1457–8.

    Article  Google Scholar 

  22. Kline JA, Nordenholz KE, Courtney DM, Kabrhel C, Jones AE, Rondina MT, Diercks DB, Klinger JR, Hernandez J. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014;12:459–68.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Instituto de Cardiologia y Medicina Vascular, TEC Salud, San Pedro Garza Garcia, Nuevo León, Mexico

    Carlos Jerjes-Sánchez M.D., F.C.C.P., F.A.C.C. (Sistema Nacional de Investigadores, Nivel II – Clinical Research Director)

  2. Escuela de Medicina, Tecnológico de Monterrey, San Pedro Garza Garcia, Nuevo León, Mexico

    Carlos Jerjes-Sánchez M.D., F.C.C.P., F.A.C.C. (Sistema Nacional de Investigadores, Nivel II – Clinical Research Director)

  3. Unidad de Investigacion Clinica en Medicina SC, Monterrey, Nuevo León, Mexico

    Carlos Jerjes-Sánchez M.D., F.C.C.P., F.A.C.C. (Sistema Nacional de Investigadores, Nivel II – Clinical Research Director)

  4. Head Pulmonary Physiology Department, Hospital de Cardiologia No 34, Instituto Mexicano del Seguro Social, Monterey, Nuevo Leon, Mexico

    Alicia Ramirez-Rivera M.D., F.C.C.P.

Authors
  1. Carlos Jerjes-Sánchez M.D., F.C.C.P., F.A.C.C.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alicia Ramirez-Rivera M.D., F.C.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlos Jerjes-Sánchez M.D., F.C.C.P., F.A.C.C. .

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Jerjes-Sánchez, C., Ramirez-Rivera, A. (2015). Thrombolytic Therapy: Evidence-Based Results from Multicenter Control Trials. In: Thrombolysis in Pulmonary Embolism. Springer, Cham. https://doi.org/10.1007/978-3-319-19707-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19707-4_3

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-19706-7

  • Online ISBN: 978-3-319-19707-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation